ORTHONET INJECTION
November 10, 2017TRANZ INJECTION
November 10, 2017
| FLUCONAZOLE I. V. |
Fluconazole 200 mg/100 ml solution for Infusion |
| Composition : |
Each ml contains 2 mg of Fluconazole.
1 vial with 100 ml solution for infusion contains 200 mg Fluconazole. |
| Indications : |
It is indicated in adults for the treatment of:Cryptococcal meningitis, Coccidioidomycosis, Invasive candidiasis,
Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis, Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.
It is indicated in adults for the prophylaxis of: Relapse of crytopcoccal meningitis in patients with high risk of recurrence; Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
• Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation.
It is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:
It is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Diflucan can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence
|
| Contraindications : |
Hypersensitivity to the active substance to related azole substances, or to any of the excipients. Co administration of terfenadine is contraindicated in patients receiving it.
|
| Adverse Effects : |
Headache, abdominal pain, vomiting, diarrhoea, nausea, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, rash |
| Dosage : |
The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.
|
